Get started
Author

Alexander Roeth

Observed names: A Roeth, A. Roeth, Roeth, A, Roeth, A., Roeth, Alexander
OpenAlex ID: A5021867932
Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial
2012 · A. Korfel, M. Weller, et al. · Annals of Oncology · 69
Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)
2022 · Gerald Illerhaus, Andrés J.M. Ferreri, et al. · Blood · 41
Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study
2022 · Regis Peffault de Latour, Alexander Roeth, et al. · Blood · 23
Imetelstat Rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) Who Are Refractory or Intolerant to Prior Therapy: Preliminary Phase II Results
2012 · Gabriela M. Baerlocher, Elisabeth Oppliger Leibundgut, et al. · Blood · 23
Sequential High Dose Immuno-Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation for Patients with Untreated Primary Central Nervous System Lymphoma - a Multicentre Study by the Collaborative PCNSL Study Group Freiburg
2012 · Gerald Illerhaus, Kristina Fritsch, et al. · Blood · 22
Factor B Inhibition with Oral Iptacopan Monotherapy Demonstrates Sustained Long-Term Efficacy and Safety in Anti-C5-Treated Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia: Final 48-Week Results from the Multicenter, Phase III APPLY-PNH Trial
2023 · Antonio M Risitano, Austin Kulasekararaj, et al. · Blood · 15
High-Dose Chemotherapy and Autologous Stem Cell Transplant in Elderly and Fit Primary CNS Lymphoma Patients - a Multicenter Study By the Cooperative PCNSL Study Group (MARTA study)
2022 · Elisabeth Schorb, Lisa Isbell, et al. · Blood · 12
Consolidative Hct‐asct Is Superior to Non‐myeloablative Chemo‐immunotherapy in Newly‐diagnosed Pcnsl ‐ Updated Results of the Randomized Phase Iii Matrix/ielsg43 Trial
2023 · G. Illerhaus, A. Ferreri, et al. · Hematological Oncology · 7
PDF
Long-Term Safety and Efficacy of Pegcetacoplan Treatment in Adults with Paroxysmal Nocturnal Hemoglobinuria
2022 · Christopher J. Patriquin, Andrija Bogdanovic, et al. · Blood · 7
Inhibition of Complement C1s By Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Efficacy and Safety Results from the Randomized, Placebo-Controlled Phase 3 CADENZA Study
2021 · Alexander Roeth, Sigbjørn Berentsen, et al. · Blood · 6
Prognostic factors for chemotherapy-related toxicity in primary central nervous system lymphoma (PCNSL) treated with high-dose methotrexate (HDMTX) with or without ifosfamide: Results from a German phase III trial (G-PCNSL-SG-1).
2011 · P. Martus, K. Jahnke, et al. · Journal of Clinical Oncology · 6
Patient Preferences and Treatment Satisfaction in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Crovalimab and Approved C5 Inhibitors in the Phase III Randomized COMMODORE 1 and COMMODORE 2 Trials
2023 · Austin Kulasekararaj, Fernando Ataulfo Gonzalez Fernandez, et al. · Blood · 5
Safety of Crovalimab Versus Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Pooled Results from the Phase III COMMODORE 1, COMMODORE 2, and COMMODORE 3 Studies
2023 · Alexander Roeth, Rong FU, et al. · Blood · 4
Sustained Complement C1s Inhibition with Sutimlimab in Patients with Cold Agglutinin Disease Results in Continued Efficacy during Part B of the Randomized Placebo-Controlled Phase 3 Cadenza Study (NCT03347422)
2022 · Alexander Roeth, Sigbjørn Berentsen, et al. · Blood · 4
Dynamics of Mutations in Patients with ET Treated with Imetelstat
2015 · Elisabeth Oppliger Leibundgut, Monika Haubitz, et al. · Blood · 3
G-PCNSL-SG-1 randomized phase III trial of high-dose methotrexate with or without whole brain radiotherapy for primary central nervous system lymphoma: Long-term follow-up.
2014 · Agnieszka Korfel, Eckhard Thiel, et al. · Journal of Clinical Oncology · 3
Development Of a Disease Specific Quality Of Life Questionnaire For Patients With Aplastic Anemia and/Or Paroxysmal Nocturnal Hemoglobinuria (QLQ-AA/PNH)
2013 · Martha Groth, Susanne Singer, et al. · Blood · 3
Systemic and intrathecal chemotherapy followed by high-dose chemotherapy with autologous stem cell transplantation (HD-ASCT) for CNS relapse of aggressive lymphomas: A potentially curative approach?
2011 · L. Fischer, M. Haenel, et al. · Journal of Clinical Oncology · 3
Extremely short telomeres and high telomerase activity in T-cell prolymphocytic leukemia (T-PLL): An optimal target for telomerase inhibition with GRN163L?
2008 · A. Roeth, D. de Beer, et al. · Journal of Clinical Oncology · 3
Biomarker Analyses in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Crovalimab and Eculizumab: Results from the Phase III Randomized COMMODORE 2 Trial
2023 · Pontus Lundberg, Silvia de la Iglesia, et al. · Blood · 2
Dose-Exposure-Response Relationships of Biomarkers and Efficacy Measures with Iptacopan, a Complement Factor B Inhibitor, in Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) with or without Concomitant Anti-C5 Therapy
2022 · Antonio Risitano, Régis Peffault de Latour, et al. · Blood · 2
Sutimlimab Provides Sustained Improvements in Patient-Reported Outcomes and Quality of Life in Patients with Cold Agglutinin Disease: Open-Label Extension of the Randomized, Phase 3 Cadenza Study
2022 · Alexander Roeth, Catherine M. Broome, et al. · Blood · 2
Hemolytic Markers, Mortality, and Thromboembolic Events in Cold Agglutinin Disease (CAD): A Retrospective Analysis of the Optum Electronic Health Record Database in the United States
2022 · Catherine M. Broome, Wilma Barcellini, et al. · Blood · 2
Long-Term Safety of Sustained Eculizumab Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria
2012 · Jeffrey Szer, Petra Muus, et al. · Blood · 2
Prognostic factors for response and survival in primary central nervous system lymphoma (PCNSL) from a randomized phase III trial (G-PCNSL-SG-1).
2011 · K. Jahnke, A. Korfel, et al. · Journal of Clinical Oncology · 2
Works count: 65
Citation count: 289
H-index: 7
I10-index: 7
Year
Topic
Type